XANTHO BIOTECHNOLOGY CO., LTD.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs. It is anticipated that the results of the Phase IIa clinical study will be available in Q2 2025.
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs. It is anticipated that the results of the Phase IIa clinical study will be available in Q2 2025.
Founded Year
2014
Unified Business No.
24558245
Status
Active
Number of Employees
0
Total Paid-in
Capital
325,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Founded in 2014, Xantho Biotechnology is dedicated to the development of botanical new drugs with low side effects from naturally derived materials, with the aim of providing new medications with improved clinical efficacy and to those with unmet medical needs. We are targeting at the botanical drug market with a global market size worth more than 40 billion USD.
